AN2 Therapeutics (ANTX) Accumulated Expenses (2021 - 2026)

AN2 Therapeutics (ANTX) has reported Accumulated Expenses for 6 consecutive years, with $1.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses fell 56.29% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (down 56.29% YoY), while the FY2025 annual figure was $2.1 million, down 53.93% from the prior year.
• Accumulated Expenses eased to $1.8 million in Q1 2026 per ANTX's latest filing, from $2.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $6.8 million in Q3 2023 and bottomed at $335000.0 in Q1 2022.
• Historically, Accumulated Expenses has averaged $3.0 million across 5 years, with a median of $2.7 million in 2025.
• Annual changes were most pronounced in 2023 — Accumulated Expenses jumped 1165.97% — and 2024, when it plunged 76.54%.
• AN2 Therapeutics' Accumulated Expenses stood at $2.2 million in 2022, then jumped by 85.33% to $4.0 million in 2023, then grew by 10.85% to $4.5 million in 2024, then plunged by 53.93% to $2.1 million in 2025, then dropped by 13.89% to $1.8 million in 2026.
• Business Quant data shows ANTX's Accumulated Expenses at $1.8 million in Q1 2026, $2.1 million in Q4 2025, and $2.7 million in Q3 2025.